Entropy Files US Patent to Lock in Rights to 75% Response Rate IBS Therapy
Entropy Neurodynamics files new US patent to protect breakthrough IBS therapy
Entropy Neurodynamics has filed US Provisional Patent Application No. 64/055,765 to strengthen intellectual property protection for its TRP-8803 IBS programme. The filing complements the existing PCT application filed 3 January 2024 and establishes multiple patent families covering the company’s psychedelic-assisted therapy platform. The application is underpinned by Phase 2a clinical data presented at Digestive Disease Week (DDW) 2026 on 4 May 2026 by researchers from Massachusetts General Hospital and Columbia University, demonstrating a 75% response rate in treatment-resistant IBS patients.
The filing arrives at a strategic inflection point where clinical data validation combined with patent protection strengthens the company’s partnering leverage in the US market.
When big ASX news breaks, our subscribers know first
Clinical results driving the patent: 75% response rate in treatment-resistant IBS
The Phase 2a study that underpins this patent filing delivered a 75% response rate in treatment-resistant IBS patients, significantly exceeding existing IBS therapies which typically demonstrate 17–44% response rates. The source announcement describes this as “the strongest clinical signal ever reported in IBS drug development.”
The study used TRP-8802 (oral psilocybin), with insights now supporting intellectual property for TRP-8803 (IV-infused psilocin), the company’s lead asset.
| Metric | TRP-8802 Phase 2a | Existing IBS Therapies |
|---|---|---|
| Response Rate | 75% | 17–44% |
| Patient Population | Treatment-resistant | Varies |
Clinical efficacy significantly exceeding current standard of care validates the therapeutic approach and strengthens the commercial case for partnering discussions. The data provides a foundation for patent claims rooted in robust human clinical evidence rather than preclinical or theoretical mechanisms.
What is treatment-resistant IBS and why does it matter?
Irritable bowel syndrome is a gut-brain disorder characterised by abdominal pain, bloating, and altered bowel habits. Treatment-resistant IBS refers to patients who have not responded adequately to existing therapies, including dietary modifications, prescription medications, and psychological interventions.
This population represents a large, underserved market with significant unmet medical need. Entropy Neurodynamics positions itself in the emerging field of gut-brain targeted psychedelic therapies, which aim to address the neurological component of these disorders that conventional treatments often fail to target effectively.
Treatment-resistant patient populations represent both a clinical challenge and a commercial opportunity. Therapies that succeed where others fail command premium positioning in licensing negotiations and reimbursement frameworks.
Building a defensible IP architecture
The new US filing complements the company’s existing patent portfolio, which includes an Australian patent covering precision-controlled psilocybin/psilocin delivery with protection through to 2042. That patent was granted 12 February 2026 and underpins TRP-8803, the company’s lead IV-infused psilocin asset.
The intellectual property architecture now spans both oral and IV-delivered psychedelic therapies, creating layered protection that supports long-term exclusivity across multiple formulation approaches and administration routes.
IP Portfolio Components:
- US Provisional Patent Application No. 64/055,765 (filed May 2026)
- PCT application (filed January 2024)
- Australian patent — precision-controlled delivery (granted February 2026, protection to 2042)
Multiple patent families across jurisdictions create defensible barriers to competition, reducing the risk of generic or follow-on products entering the market prior to patent expiry. This layered protection enhances strategic value for licensing or partnering transactions, as potential partners can model revenue streams with greater certainty around exclusivity periods.
CEO commentary
Chief Executive Officer Jason Carroll emphasised the strategic timing of the filing and its foundation in human clinical data:
Jason Carroll, CEO
“Building on our existing PCT application and TRP-8803 patent portfolio, this filing materially strengthens Entropy’s IP position at a critical inflection point in clinical development. Importantly, the application is grounded in robust, human clinical data, reinforcing both the novelty and translational relevance of our approach in treatment-resistant IBS.”
Carroll also highlighted the broader platform implications:
Jason Carroll, CEO
“We believe this expanded IP architecture establishes a defensible and scalable foundation across both oral and IV-delivered psychedelic therapies, supporting long-term exclusivity in a large, underserved market. It also enhances the strategic value of TRP-8803 as we advance our US-focused development and partnering initiatives, positioning Entropy as a leader in the emerging field of gut-brain targeted psychedelic therapies.”
The next major ASX story will hit our subscribers first
US-focused strategy and next steps
The company is advancing US-focused development and partnering initiatives, aligning its clinical and commercial strategy with the jurisdiction that offers the largest addressable market for novel IBS therapies. The US patent filing supports this geographical focus by establishing protection in the market where licensing and commercialisation discussions are most likely to occur.
Entropy Neurodynamics has scheduled an investor webinar for 10:30am AEST (8:30am AWST) on Wednesday, 6 May 2026, hosted by CEO Jason Carroll. The webinar will include a question-and-answer session, with questions accepted via email prior to the event or in written form during the session. A recording will be made available following the webinar.
Management accessibility and proactive investor communication signals confidence in the strategic direction. The US market focus aligns with where the largest commercial opportunities exist for novel IBS therapies, both in terms of patient populations and premium pricing dynamics for first-in-class treatments addressing unmet medical needs.
Ready to Learn More About Entropy Neurodynamics’ Patent-Protected IBS Therapy?
With a 75% response rate in treatment-resistant patients and multiple patent families now protecting its psychedelic-assisted platform, Entropy Neurodynamics is positioning itself at the forefront of gut-brain therapeutics. The recent US filing strengthens IP protection for TRP-8803 ahead of critical partnering discussions.
To explore the company’s clinical pipeline, intellectual property strategy, and upcoming investor webinar, visit the Entropy Neurodynamics investor centre. Discover how this ASX-listed biotech is building a defensible position in a large, underserved market.